Jianqing Xu, Ph.D, M.MSc, B.MSc

Education

 1994-1997        Ph.D, Chinese Academy of Medical Sciences & Peking Union Medical College

1991-1994        M.MSc, China Medical University, Shenyang

1986-1991        B.MSc, China Medical University, Shenyang

Work Experiences

 2021-present     Professor and Principal Investigator, PhD Supervisor, Zhongshan Hospital, Fudan University

 2014-present     Tenured Professor and Principal Investigator, PhD Supervisor, Institutes of Biomedical Sciences, Fudan University

 2007-2021        Professor and Principal Investigator, PhD Supervisor, Shanghai Public Health Center, Fudan University

 2007-2014        Professor and Principal Investigator, PhD Supervisor, Institutes of Biomedical Sciences, Fudan University

 2004-2007        Principal Investigator, Center for HIV/AIDS Prevention and Control, China CDC

 2001-2004        Research assistant professor, Department of Microbiology and Immunology, Georgetown University, Washington DC

 1997-2001        Postdoctoral research fellow, Research Institute for Genetic and Human Therapy affiliated to Georgetown University, Washington DC

Contact

Institutes of Biomedical Sciences, Fudan University,

Shanghai 200032

Tel: 86-18964630206 or 86-15921220206

Email: xujianqing@fudan.edu.cn

Lab homepage: http://www.hiv.fudan.edu.cn/

Biograph

Dr. Jianqing Xu graduated from China Medical University with bachelor's and master's degree, received his Ph.D. in Microbiology from Peking Union Medical College (1997), and pursued his postdoctoral research in Research Institute for Genetic and Human Therapy affiliated to Georgetown University and appointed as Research Assistant professor at Department of Microbiology and Immunology in 2001. He then joined in China CDC HIV/AIDS Center as Principal Investigator in 2004. Four years later, he moved to Fudan University to take a professorship position and became tenured professor in Fudan University in 2014.

Research Areas

• Immune protective mechanism and immune-pathogenesis during viral infection

• Development of immunotherapy, drugs, and vaccines against infection

• Development of novel tumor immunotherapy techniques

Research Interests and Major Achievements

1. Dissect protective immunity and immune pathogenesis during acute and chronic infection: It is critical to understand the protective immunity and pathogenesis during infection in order to develop effective vaccines and new medicines. During last more than a decade, my group has been working on HIV, influenza and COVID-19 clinical cohorts to systemically examine innate, humoral and cellular immune responses, and to enlighten the immune protective mechanism and immune pathogenesis. For example, in the H7N9 infection cohort, we systemically explored roles for both innate and adaptive immunity, identified that the deficiency of type I IFN pathway could result in the severe or even fatal infection by H7N9 though the anti-flu medicine were administrated as early as possible (PNAS, 2014, highly citated); Early type I IFN response contains viral replication and thereby restrains disease progression (Sci Signaling. 2020); In addition, early influenza-specific T cell responses correlates with early containment of viral replication and early release from hospitalization (Nat Commun, 2015), failing to elicit neutralization antibodies (EuroSurveillance, 2013) or inducing exhausted T cell responses (Nat Commun, 2018) are associated with fatal infection. Sequential infection/immunization with different influenza or influenza vaccines leads to the development of broad neutralization antibody responses (JCI Insight, 2017; J Infect Dis, 2017, Clin Infect Dis, 2012). Interestingly, regulatory arm on inflammation usually plays protective roles, such as IL-37 in COVID-19 (J Infect Dis, 2021) and Ly6E in HIV-1 infection (J Immunol, 2014); In contrast, up-regulation of inflammation fuels the progression (J Virol. 2017; J Infect Dis, 2018). Furthermore, Enhancing viral-specific T cell functionalities could improve the containment of viral replication (Nature, 2016; Front Immunol. 2020; Natl Review Sciences, 2024) whereas suppression facilitates disease progression (J Immunol, 2015). Furthermore, CD160 improves the development of effective memory T cells (J Immunol, 2023), the kinase complex mTORC2 promotes the longevity of virus-specific memory CD4+ T cells by preventing ferroptosis (Nature Immunol, 2022)

2. Explore the interaction between host cells and viruses: It is important for the development of novel intervention strategies to explore interaction between host cells and viruses. By employing cell-based HIV, influenza, ZIKV and SARS-CoV-2 infection model, we have identified a number of host factors which are engaged in the interaction between cell and virus, such as AXL as a suppressor of type-I IFN pathway to promote the survival of ZIKV (Nature Microbiology, 2018), TSC1 and DEPDC5 as regulators of HIV latency (Emerg Microbes Infect., 2018), NCAM1 as a ZIKV receptor (Nature Communication, 2020), ALPP as a docking molecule for ZIKV assembling (mBio, 2020; Editor recommendation), MyH9 as a co-receptor of SARS-CoV-2 (PNAS, 2022).

3. Develop vaccination strategies, vaccine vector, vaccines and immune medicines against infections: To develop an effective vaccine, we tested different vaccination combinations, including as following: Sequential inoculation with different HIV Env immunogens to mount preferential T cell responses to conserved epitopes (AIDS, 2006; Curr Opin Immunol. 2018), mucosal priming and systemic boosting to raise vigorous respiratory immunity (Vaccine, 2007A/2007B), DNA priming and vaccinia vectored vaccine boost to enhance the T-cell functional avidity (J Virol, 2014), and A Systemic Prime-Intrarectal Pull Strategy Raises Rectum-Resident CD8+ T Cells (Front Immunol, 2020).

My group also explore different vaccine vectors, such as PEGylated poly [2-(N, N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector (Biomaterials, 2010), adenoviral and vaccinia vectors (Front Microbiol, 2019). In addition, we develop two potential universal vaccine against influenza (Front Microbiol, 2019; Emerg Microb Infect, 2024), three vaccines against COVID-19 (Emerg Microbes Infect. 2021; J Virol, 2021; NPG Vaccine, 2024), an combination medicine of TFF2 plus IFN-kappa and shown effective in clinic for COVID-19 patients (EClinicalMedicine, 2020A/2020B), one neutralization antibody (Cell report, 2020) and one broad neutralization antibody against SARS-CoV-2 (Nature Microbiology, 2022). In addition, his group developed a novel triple functional CAR-T against HIV-1 with a potential to achieve functional cure (Cell Discov., 2024)

4. Develop new therapeutics against solid tumors: We examined and identified the correlation of CTL responses to HSP47 with the prolonged survival of glioblastomas patients (Neurology, 2014), developed one hypoxia-activated CAR-T (BioMarker Research, 2020) and one double pathway optimized CAR-T (BioMarker Research, 2021). In addition, we further developed a highly hypoxia-sensitive CAR-T (Journal of Immunotherapy for Cancer, JITC, 2021) and a vaccinia based oncolytic virus (JITC, 2021, IF=13.75).

Selected Publications

 *indicated the corresponding author. More than 240 scientific papers have been published in total. More published papers can be viewed on Prof Xu’s Research Gate profile (https://www.researchgate.net/profile/Jianqing-Xu-2).

1. Jia X, Crawford JC, Gebregzabher D, Monson EA, Mettelman RC, Wan Y,  Ren Y, Chou J, Novak T, McQuilten HA, Clarke M, Bachem A, Foo IJ, Fritzlar S, Montoya JC, Trenerry AM, Nie S, Leeming MG, Nguyen THO, Kedzierski L, Littler D, Kueh A, Cardamone T, Wong C, Hensen L, Cabug A1, Gómez Laguna J, Agrawal M, Flerlage T, Boyd DF, Van de Velde LE, Habel JR, Loh L, Koay HF, van de Sandt C, Konstantinov IE, Berzins SP, Flanagan KL, Wakim LM, Herold MJ, Green AM, Smallwood HS, Rossjohn J, Thwaites RS, Chiu C, Scott NE, Mackenzie JM, Bedoui S, Reading PC, Londrigan SL, Helbig KJ, Randolph AG, Thomas PG, Xu J, Wang Z, Chua and Kedzierska K. High expression of oleoyl-ACP-hydrolase underpins life-threatening respiratory viral diseases. Cell. 2024 (in press).

2. Mao Y, Liao Q, Zhu Y, Bi M, Zou J, Zheng N, Zhu L, Zhao C, Liu Q, Liu L, Chen J, Gu L, Liu Z, Pan X, Xue Y, Feng M, Ying T, Zhou P, Wu Z, Xiao J, Zhang R*, Leng J*, Sun Y*, Zhang X*, Xu J*. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov. 2024 May 14;10(1):49. doi: 10.1038/s41421-024-00658-z.

3. Zhou P, Qiu T, Wang X, Yang X, Shi H, Zhu C, Dai W, Xing M, Zhang X, Xu J*, Zhou D*. One HA stalk topping multiple heads as a novel influenza vaccine. Emerg Microbes Infect. 2024 Dec;13(1):2290838. doi: 10.1080/22221751.2023.2290838. 

4. Xing M, Hu G, Wang X, Wang Y, He F, Dai W, Wang X, Niu Y, Liu J, Liu H, Zhang X, Xu J*, Cai Q*, Zhou D*. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines. 2024 Mar 21;9(1):64. doi: 10.1038/s41541-024-00857-5.

5. Xingyue Wu, Yao Chen, Kangli Cao, Yao Shen, Xueling Wu, Yilin Yang, Zhongshu Kuang, Qingrun Li, Zhenzhen Lu, Yichen Jia, Mian Shao, Guorong Gu, Xiangwei Wang, Ye Yao, Ying Wang, Shaodie Chen, Zhigao Yu, Wei Wei, Longfei Ding, Lulu Lan, Tianwen Gu, Xiangyu Long, Jian Sun, Lingyu Xing, Jiayuan Shen, Yi Han, Yue Luo, Sucheng Mu, Mengna Lin, Xiaoyan Zhang, Rong Zeng, Jianqing Xu*, Guoping Zhao*, Lihong Huang*, Zhenju Song*, Reduced clinical severity during 2022 Shanghai Spring epidemic of SARS-CoV-2 omicron BA.2 variant infection - An integrated account of virus pathogenicity and vaccination effectiveness, National Science Review, 2024;, nwae011, https://doi.org/10.1093/nsr/nwae011

6. Zhou P, Qiu T, Wang X, Yang X, Shi H, Zhu C, Dai W, Xing M, Zhang X, Xu J*, Zhou D*. One HA stalk topping multiple heads as a novel influenza vaccine. Emerg Microbes Infect. 2023 Dec 4:2290838. doi: 10.1080/22221751.2023.2290838. 

7. Zhang L, Zhang A, Zhu X, Tian X, Guo J, He Q, Zhu L, Yuan S, Zhao C*, Zhang X*, Xu J*. CD160 Signaling Is Essential for CD8+ T Cell Memory Formation via Upregulation of 4-1BB. J Immunol. 2023 Nov 1;211(9):1367-1375. doi: 10.4049/jimmunol.2200792.

8. Gao R, Li A, Li S, Li X, Zhang S, Zhang X*, Xu J*. Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease. Am J Transplant. 2023 Jul;23(7):946-956. doi: 10.1016/j.ajt.2023.04.017. 

9. Qibin Liao#, Huan He#, Zhuoqun Liu#, Cuisong Zhu, Meiqi Feng, Lang Jiang, Xiangqing Ding, Xiaoyan Zhang*, Jianqing Xu*. Rapid generation of a mouse model for evaluating on-target normal tissue toxicity of human CAR-T cells using replication-defective recombinant adenovirus. Journal of Advanced Research. 2023 May; 47:163-171. doi: 10.1016/j.jare.2022.08.008.

10. Lin M, Cao K, Xu F, Wu X, Shen Y, Lu S, Kuang Z, Ding H, Yuan S, Shao M, Gu G, Xing L, Gu T, Chen S, Sun J, Zhu J, Zhang X, Yang Y, Zhao G*, Huang L*, Xu J*, Song Z*. A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China. Emerg Microbes Infect. 2023 Dec;12(2):2261559. doi: 10.1080/22221751.2023.2261559.

11. Xiaoyu Sun, Chunyan Yi, Yuanfei Zhu, Longfei Ding, Shuai Xia, Xingchen Chen, Mu Liu, Chenjian Gu, Xiao Lu, Yadong Fu, Shuangfeng Chen, Tianlong Zhang,Yaguang Zhang, Zhuo Yang, Liyan Ma, Wangpeng Gu, Gaowei Hu, Shujuan Du, Renhong Yan, Weihui Fu, Songhua Yuan, Chenli Qiu, Chen Zhao, Xiaoyan Zhang, Yonghui He, Aidong Qu, Xu Zhou, Xiuling Li, Gary Wong, Qiang Deng, Qiang Zhou, Hongzhou Lu, Zhiyang Ling*, Jianping Ding*, Lu Lu*, Xu J*, Youhua Xie* and Bing Sun* . Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nature Microbiology, 2022, 7(7):1063-1074. doi: 10.1038/s41564-022-01155-3.

12. Wang Y, Tian Q, Hao Y, Yao W, Lu J, Chen C, Chen X, Lin Y, Huang Q, Xu L, Hu J, Lei S, Wei Z, Luo Y, Li Z, Hu L, Tang J, Wu Q, Zhou X, Wu Y, Yin Z*, Xu J*, Ye L*. The kinase complex mTORC2 promotes the longevity of virus-specific memory CD4+ T cells by preventing ferroptosis. Nat Immunol. 2022 Feb;23(2):303-317. doi: 10.1038/s41590-021-01090-1.

13. Cheng X, Wang J, Qiu C, Jin Y, Xia B, Qin R, Hu H, Yan J, Zhang X*, Xu J*. Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial. Clin Immunol. 2022 Mar 30;238:108992. doi: 10.1016/j.clim.2022.108992.

14. Cao K, Wang X, Peng H, Ding L, Wang X, Hu Y, Dong L, Yang T, Hong X, Xing M, Li D, Zhu C, He X, Zhao C, Zhao P, Zhou D*, Zhang X*, Xu J*. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. J Virol. 2022 Feb 23;96(4): e0157821. doi: 10.1128/JVI.01578-21. 

15. Li W, Yang S, Xu P, Zhang D, Tong Y, Chen L, Jia B, Li A, Lian C, Ru D, Zhang B, Liu M, Chen C, Fu W, Yuan S, Gu C, Wang L, Li W, Liang Y, Yang Z, Ren X, Wang S, Zhang X, Song Y, Xie Y, Lu H, Xu J*, Wang H*, Yu W*. SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. EBioMedicine. 2022 Feb;76:103861. doi: 10.1016/j.ebiom.2022.103861. 

16. Wang J, Zhang R, Ding X, Jin Y, Qin R, Xia B, Liao Q, Hu H, Song W, Wang Z, Zhang X, Xu J*. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient. Immunotherapy. 2022 Apr 20. doi: 10.2217/imt-2021-0247. 

17. Chen J, Liu J, Chen Z, Peng H, Zhu C, Feng D, Zhang S, Zhao P, Zhang X, Xu J*. Angiotensin-Converting Enzyme 2 Potentiates SARS-CoV-2 Infection by Antagonizing Type I Interferon Induction and Its Down-Stream Signaling Pathway. mSphere. 2022 Aug 31;7(4):e0021122. doi: 10.1128/msphere.00211-22. Epub 2022 Jul 12.

18. Wang Y, Qian G, Zhu L, Zhao Z, Liu Y, Han W, Zhang X, Zhang Y, Xiong T, Zeng H, Yu X, Yu X, Zhang X, Xu J*, Zou Q*, Yan D*. HIV-1 Vif suppresses antiviral immunity by targeting STING. Cell Mol Immunol. 2022 Jan;19(1):108-121. doi: 10.1038/s41423-021-00802-9.

19. Xiangchuan He, Longfei Ding, Kangli Cao, Haoran Peng, Chenjian Gu, Yutang Li, Duoduo Li, Lanlan Dong, Xiujing Hong, Xiangwei Wang, Meilan Fu, Chenli Qiu, Cuisong Zhu, Ziling Zhang, Shu Song, Chenguang Wang, Zhengfan Jiang, Youhua Xie, Zhongtian Qi, Chen Zhao, Ping Zhao, Xiaoyan Zhang, Xu J*. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. Emerg Microbes Infect. 2021;10(1):1555-1573.

20. Jian Chen, Jun Fan, Zhilu Chen, Miaomiao Zhang, Haoran Peng, Jian Liu, Longfei Ding, Mingbin Liu, Chen Zhao, Ping Zhao *, Shuye Zhang,*, Xiaoyan Zhang*, Xu J*. Nonmuscle myosin heavy chain IIA facilitate SARS-CoV-2 infection in human pulmonary cells. PNAS, 2021, 118: No. 00 e2111011118. https://doi.org/10.1073/pnas.2111011118.

21. Huan He#, Qibin Liao#, Cuisong Zhu, Meiqi Feng, Lang Jiang, Zhuoqun Liu, Xiangqing Ding, Xiaoyan Zhang*, Jianqing Xu*. Conditioned CAR-T Cells by Hypoxia-inducible Transcription Amplification (HiTA) System Significantly Enhances Systemic Safety and Retains Anti-tumor Efficacy. J Immunother Cancer. 2021 Oct; 9(10):e002755. doi: 10.1136/jitc-2021-002755.

22. Huang L, Ding L, Zhou J, Chen S, Chen F, Zhao C, Xu J*, Hu W*, Ji J*, Xu H*, Liu GL*. One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device. Biosens Bioelectron. 2021 Jan 1;171:112685. doi: 10.1016/j.bios.2020.112685.

23. Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C*, Zhang X*, Xu J*. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J Immunother Cancer. 2021 Jan;9(1): e001647. doi: 10.1136/jitc-2020-001647.

24. Srivastava M, Zhang Y, Chen J, Sirohi D, Miller A, Zhang Y, Chen Z, Lu H, Xu J*, Kuhn RJ*, Andy Tao W*. Chemical proteomics tracks virus entry and uncovers NCAM1 as Zika virus receptor. Nat Commun. 2020; 11(1):3896. doi: 10.1038/s41467-020-17638-y.

25. Liao Q, He H, Mao Y, Ding X, Zhang X*, Xu J*. Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark Res. 2020. 8: 56. doi: 10.1186/s40364-020-00238-9.

26. Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, Rong B, Li C, Wang S, Chen K, He C, Zhu D, Yuan S, Qiu C, Zhao C, Nie L, Gao Z, Jiao J, Zhang X, Wang X, Ying T, Wang H, Xie Y, Lu Y, Xu J*, Lan F*. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Rep. 2020 Jul 21;32(3):107918. doi: 10.1016/j.celrep.2020.107918.

27. Fu W, Liu Y, Liu L, Hu H, Cheng X, Liu P, Song Z, Zha L, Bai S, Xu T, Yuan S, Lu F, Shang Z, Zhao Y, Wang J, Zhao J, Ding L, Chen J, Zhang L, Zhu T*, Zhang X*, Lu H*, Xu J*. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. EClinicalMedicine （Lancet group）. 2020. 27:100547. doi: 10.1016/j.eclinm.2020.100547. （Web feature article）

28. Fu W, Liu Y, Xia L, Li M, Song Z, Hu H, Yang Z, Wang L, Cheng X, Wang M, Jiang R, Liu L, Mao X, Chen J, Ling Y, Zhang L, Yan J, Shan F, Steinhart C, Zhang X*, Zhu T*, Xu J*, Lu H*. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19. EClinicalMedicine. 2020. 25:100478. doi: 10.1016/j.eclinm.2020.100478.

29. Zhang T, Chen X, Liao G, Hu M, Xu J*, Xu X*. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines. J Med Virol. 2020. doi: 10.1002/jmv.25690.

30. Liao Q, Mao Y, He H, Ding X, Zhang X*, Xu J*. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. Biomark Res. 2020. 8: 57. doi: 10.1186/s40364-020-00237-w.

31. He Y, Fu W, Cao K, He Q, Ding X, Chen J, Zhu L, Chen T, Ding L, Yang Y, Zhu C, Yuan S, Li Z, Zhao C, Zhang X*, Xu J*. IFN-κ suppresses the replication of influenza A viruses through the IFNAR-MAPK-Fos-CHD6 axis. Sci Signaling. 2020. 13: eaaz3381. doi: 10.1126/scisignal.aaz3381. （Coverage Story）

32. Chen J, Chen Z, Liu M, Qiu T, Feng D, Zhao C, Zhang S*, Zhang X*, Xu J*. Placental Alkaline Phosphatase Promotes Zika Virus Replication by Stabilizing Viral Proteins through BIP. mBio . 2020. 11: e01716-20. doi: 10.1128/mBio.01716-20. （Editor Recommendation）

33. Qiu T, Yang Y, Qiu J, Huang Y, Xu T, Xiao H, Wu D, Zhang Q, Zhou C, Zhang X, Tang K, Xu J*, Cao Z*. CE-BLAST makes it possible to compute antigenic similarity for newly emerging pathogens. Nature Communication, 2018, 9(1): 1772

34. Wang Z, Zhu L, Nguyen T, Wan Y, Sant S, Quiñones-Parra S, Crawford J, Eltahla A, Rizzetto S, Bull R, Qiu C, Koutsakos M, Clemens B, Loh L, Chen T, Liu L, Cao P, Ren Y, Kedzierski L, Kotsimbos T, McCaw J, Gruta N, Turner S, Cheng A, Luciani F, Zhang X, Doherty P, Thomas P, Xu J* and Kedzierska K* Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nature Communication, 2018, 9: 824

35. Jian Chen, Yi-feng Yang, Yu Yang, Peng Zou, Jun Chen, Yongquan He, Sai-lan Shui, Yan-ru Cui, Ru Bai, Ya-jun Liang, Yunwen Hu, Biao Jiang, Lu Lu, Xiaoyan Zhang*, Jia Liu*, Xu J*. AXL Promotes Zika Virus Infection in Astrocytes by Antagonizing Type I Interferon Signaling. Nature Microbiology, 2018, 3(3): 302-309. doi: 10.1038/s41564-017-0092-4.

36. Jin S, Liao Q, Chen J, Zhang L, He Q, Zhu H, Zhang X*, Xu J*. TSC1 and DEPDC5 regulate HIV-1 latency through the mTOR signaling pathway. Emerg Microbes Infect.2018; 7(1):138. doi: 10.1038/s41426-018-0139-5.

37. Zhao C*, Xu J*. Toward universal influenza virus vaccines: from natural infection to vaccination strategy. Curr Opin Immunol . 2018，53:1-6.

38. Chen J, Yang YF, Chen J, Zhou X, Dong Z, Chen T, Yang Y, Zou P, Jiang B, Hu Y, Lu L, Zhang X, Liu J*, Xu J*, Zhu T*. Zika virus infects renal proximal tubular epithelial cells with prolonged persistency and cytopathic effects. Emerg Microbes Infect. 2017 Aug 23;6(8):e77. doi: 10.1038/emi.2017.67.

39. Ran He, Shiyue Hou, Cheng Liu, Anli Zhang, Qiang Bai, Miao Han, Yu Yang, Gang Wei, Ting Shen, Xinxin Yang, Lifan Xu, Xiangyu Chen, Yaxing Hao, Chuhong Zhu, Juanjuan Ou, Houjie Liang, Ting Ni, Xiaoyan Zhang, Xinyuan Zhou, Xu J, Hai Qi*, Yuzhang Wu* and Lilin Ye*. Follicular CXCR5-expressing CD8 T cells curtail chronic viral infection. Nature, 2016, 537 (7620):412-428. doi: 10.1038/nature19317.

40. Liyen Loh, Zhongfang Wang, Sneha Sant, Marios Koutsakos, Sinthujan Jegaskanda, Alexandra J Corbett, Ligong Liu, David P Fairlie, Jane Crowe, Jamie Rossjohn, Xu J, Peter C Doherty, James McCluskey, Katherine Kedzierska. Human mucosal-associated invariant T cells contribute to anti-viral influenza immunity via IL-18 dependent activation. PNAS, 2016; 113(36):10133-8. doi: 10.1073/pnas.1610750113.

41. Wang Z, Wan Y, Qiu C, Quiñones-Parra S, Zhu Z, Loh L, Tian D, Ren Y, Hu Y, Zhang X, Thomas PG, Inouye M, Doherty PC, Kedzierska K*, Xu J*. Rapid recovery from severe H7N9 disease requires a diversity of response mechanisms dominated by CD8+ T cells. Nat. Communication. 2015, 6: 6833. doi: 10.1038/ncomms7833.

42. Zhe Bao Wu, Lin Cai, Chao Qiu, An Li Zhang, Shao Jian Lin, Yu Yao, Xu J*, and Liangfu Zhou*. CTL responses to HSP47 associated with the prolonged survival of glioblastomas patients. Neurology, 2014, 82(14):1261-5.

43. Qiu C, Yuan S, Tian D, Yang Y, Zhang A, Chen Q, Wan Y, Song Z, He J, Li L, Sun J, Zhou M, Qiu C, Zhang Z, Lu S, Zhang X, Hu Y, Xu J*. Epidemiologic report and serologic findings for household contacts of three cases of influenza A (H7N9) virus infection. J Clin Virol. 2014; 59(2):129-31.

44. Meng Z, Han R, Hu Y, Yuan Z, Jiang S, Zhang X, Xu J*. Possible pandemic threat from new reassortment of influenza A(H7N9) virus in China. EuroSurveill. 2014; 19(6):pii=20699. Available online: http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=20699

45. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M, Li L, Zhou M, Yuan S, Sun J, Zhu Z, Chen L, Li Q, Zhang Z, Zhang X*, Lu S, Doherty PC, Kedzierska K*, Xu J*. Early hypercytokinemia is associated with IFITM3 dysfunction and predictive of fatal H7N9 infection. PNAS, 2014, 111:769-74.

46. Zhang A, Huang Y, Tian D, Lau EH, Wan Y, Liu X, Dong Y, Song Z, Zhang X, Zhang J, Bao M, Zhou M, Yuan S, Sun J, Zhu Z, Hu Y, Chen L, Leung CY, Wu JT, Zhang Z, Zhang X, Peiris JS, Xu J*. Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013 . Eurosurveillance. 2013; 18(50):pii=20657.

47. Qiu, C., Y. Huang, A. Zhang, D. Tian, Y. Wan, X. Zhang, W. Zhang, Z. Zhang, Z. Yuan, Y. Hu, X. Zhang, and Xu J*. Safe Pseudovirus-based Assay for Neutralization Antibodies against Influenza A(H7N9) Virus. Emerg Infect Dis 2013. 19: 1685-87.

48. Qiu C, Huang Y, Wang Q, Tian D, Zhang W, Hu Y, Yuan Z, Zhang X*, Xu J*. Boosting Heterosubtypic Neutralization Antibodies in Recipients of 2009 Pandemic H1N1 Influenza Vaccine. Clinical Infectious Diseases, 2012. 54: 17-24.

49. Yong Qiao, Yang Huang, Chao Qiu, Xinye Yue, Liandong Deng, Yanmin Wan, Jinfeng Xing, Congyou Zhang, Songhua Yuan, Anjie Dong*, Xu J*. The Use of PEGylated Poly [2-(N, N-dimethylamino) ethyl methacrylate] as A Mucosal DNA Delivery Vector and the Activation of Innate Immunity and Improvement of HIV-1-specific Immune Responses. Biomaterials,  31 (2010)： 115–123.

50. Liu, S., C. Qiu, R. Miao, J. Zhou, W. Fu, L. Zhu, L. Zhang, Xu J, M. Fu, and T. Wang. 2013. MCPIP1 restricts HIV infection and is rapidly degraded in activated CD4+ T cells. PNAS 2013;110(47):19083-8. doi: 10.1073/pnas.1316208110.

51. Lori F, Lewis M, Xu J, Varga G, Zinn D, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C & Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early infection. Science, 290: 1591~93, 2000. （The major postdoc to take this project）